(GILD) Gilead Sciences - Ratings and Ratios
HIV/Aids Therapeutics, Hepatitis Medications, Oncology Therapies, Antiviral Drugs, Pulmonary Arterial Hypertension
Dividends
| Dividend Yield | 3.16% |
| Yield on Cost 5y | 7.86% |
| Yield CAGR 5y | 3.16% |
| Payout Consistency | 100.0% |
| Payout Ratio | 38.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 25.1% |
| Value at Risk 5%th | 38.8% |
| Relative Tail Risk | -5.94% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.17 |
| Alpha | 32.22 |
| CAGR/Max DD | 0.62 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.337 |
| Beta | 0.358 |
| Beta Downside | 0.373 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.59% |
| Mean DD | 8.56% |
| Median DD | 7.58% |
Description: GILD Gilead Sciences December 02, 2025
Gilead Sciences (NASDAQ:GILD) is a U.S.-based biopharmaceutical firm that discovers, develops, and markets medicines for unmet medical needs worldwide, with a product lineup that spans HIV/AIDS (e.g., Biktarvy, Truvada), viral hepatitis (e.g., Epclusa, Harvoni), COVID-19 (Veklury), oncology (Yescarta, Trodelvy), pulmonary arterial hypertension (Letairis), and serious fungal infections (AmBisome). The company also maintains a broad network of collaborations with firms such as Merck, Galapagos, and Arcus to expand its pipeline.
In FY 2024 Gilead reported $27.3 billion in total revenue, a 5% year-over-year increase driven largely by growth in its HIV and oncology franchises, while R&D expenses rose to $5.1 billion, reflecting intensified investment in next-generation antiviral and cell-therapy candidates. The firm’s cash conversion cycle remains strong, generating $4.2 billion of free cash flow, which supports dividend payouts and share-repurchase programs.
Key sector drivers that will shape Gilead’s outlook include the ongoing pressure on drug pricing in the United States, the expiration of major HIV patents that could erode market share, and the accelerating adoption of gene-editing and cell-based therapies that may reshape competitive dynamics in oncology and infectious disease. Macro-economic factors such as U.S. healthcare spending growth (~4% CAGR) and foreign exchange volatility also affect the company’s international earnings.
For a data-rich, model-based assessment of how these variables translate into valuation risk and upside, a quick look at ValueRay’s GILD analytics can help you identify any hidden catalysts before you commit capital.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (8.11b TTM) > 0 and > 6% of Revenue (6% = 1.75b TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA -1.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 19.17% (prev 10.80%; Δ 8.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 9.67b > Net Income 8.11b (YES >=105%, WARN >=100%) |
| Net Debt (17.61b) to EBITDA (13.67b) ratio: 1.29 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.25b) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 78.71% (prev 76.11%; Δ 2.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.45% (prev 51.90%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.70 (EBITDA TTM 13.67b / Interest Expense TTM 1.02b) >= 6 (WARN >= 3) |
Altman Z'' 3.00
| (A) 0.10 = (Total Current Assets 17.87b - Total Current Liabilities 12.30b) / Total Assets 58.53b |
| (B) 0.22 = Retained Earnings (Balance) 12.82b / Total Assets 58.53b |
| (C) 0.19 = EBIT TTM 10.90b / Avg Total Assets 56.53b |
| (D) 0.35 = Book Value of Equity 12.86b / Total Liabilities 37.08b |
| Total Rating: 3.00 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.17
| 1. Piotroski 6.0pt |
| 2. FCF Yield 5.21% |
| 3. FCF Margin 31.50% |
| 4. Debt/Equity 1.16 |
| 5. Debt/Ebitda 1.29 |
| 6. ROIC - WACC (= 13.72)% |
| 7. RoE 40.70% |
| 8. Rev. Trend 43.75% |
| 9. EPS Trend 11.87% |
What is the price of GILD shares?
Over the past week, the price has changed by -0.75%, over one month by +1.87%, over three months by +11.08% and over the past year by +36.18%.
Is GILD a buy, sell or hold?
- Strong Buy: 15
- Buy: 4
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GILD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 130.6 | 5.1% |
| Analysts Target Price | 130.6 | 5.1% |
| ValueRay Target Price | 150.5 | 21% |
GILD Fundamental Data Overview November 29, 2025
P/E Trailing = 19.7384
P/E Forward = 14.5138
P/S = 5.4394
P/B = 7.3444
P/EG = 0.2323
Beta = 0.334
Revenue TTM = 29.09b USD
EBIT TTM = 10.90b USD
EBITDA TTM = 13.67b USD
Long Term Debt = 22.14b USD (from longTermDebt, last quarter)
Short Term Debt = 2.81b USD (from shortTermDebt, last quarter)
Debt = 24.94b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 17.61b USD (from netDebt column, last quarter)
Enterprise Value = 175.81b USD (158.22b + Debt 24.94b - CCE 7.35b)
Interest Coverage Ratio = 10.70 (Ebit TTM 10.90b / Interest Expense TTM 1.02b)
FCF Yield = 5.21% (FCF TTM 9.16b / Enterprise Value 175.81b)
FCF Margin = 31.50% (FCF TTM 9.16b / Revenue TTM 29.09b)
Net Margin = 27.88% (Net Income TTM 8.11b / Revenue TTM 29.09b)
Gross Margin = 78.71% ((Revenue TTM 29.09b - Cost of Revenue TTM 6.19b) / Revenue TTM)
Gross Margin QoQ = 79.80% (prev 78.80%)
Tobins Q-Ratio = 3.00 (Enterprise Value 175.81b / Total Assets 58.53b)
Interest Expense / Debt = 1.03% (Interest Expense 256.0m / Debt 24.94b)
Taxrate = 16.18% (589.0m / 3.64b)
NOPAT = 9.14b (EBIT 10.90b * (1 - 16.18%))
Current Ratio = 1.45 (Total Current Assets 17.87b / Total Current Liabilities 12.30b)
Debt / Equity = 1.16 (Debt 24.94b / totalStockholderEquity, last quarter 21.54b)
Debt / EBITDA = 1.29 (Net Debt 17.61b / EBITDA 13.67b)
Debt / FCF = 1.92 (Net Debt 17.61b / FCF TTM 9.16b)
Total Stockholder Equity = 19.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.86% (Net Income 8.11b / Total Assets 58.53b)
RoE = 40.70% (Net Income TTM 8.11b / Total Stockholder Equity 19.93b)
RoCE = 25.93% (EBIT 10.90b / Capital Employed (Equity 19.93b + L.T.Debt 22.14b))
RoIC = 20.17% (NOPAT 9.14b / Invested Capital 45.31b)
WACC = 6.45% (E(158.22b)/V(183.16b) * Re(7.33%) + D(24.94b)/V(183.16b) * Rd(1.03%) * (1-Tc(0.16)))
Discount Rate = 7.33% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.08%
[DCF Debug] Terminal Value 77.65% ; FCFE base≈9.27b ; Y1≈8.89b ; Y5≈8.66b
Fair Price DCF = 124.5 (DCF Value 154.50b / Shares Outstanding 1.24b; 5y FCF grow -5.51% → 3.0% )
EPS Correlation: 11.87 | EPS CAGR: 40.51% | SUE: 1.63 | # QB: 1
Revenue Correlation: 43.75 | Revenue CAGR: 1.88% | SUE: 1.15 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.05 | Chg30d=+0.077 | Revisions Net=+2 | Analysts=7
EPS next Year (2026-12-31): EPS=8.72 | Chg30d=+0.116 | Revisions Net=+4 | Growth EPS=+6.8% | Growth Revenue=+3.0%
Additional Sources for GILD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle